Liver disease, particularly when it progresses to cirrhosis, tends to push A1C readings falsely low, sometimes dramatically so. A person with genuine diabetes can show an A1C that looks normal or even below normal, masking dangerously poor blood sugar control. One study of people with diabetes and cirrhosis found their median A1C was about 5.9%, while people with the same degree of diabetes but no cirrhosis had a median A1C of 7.7%, despite similar actual blood sugar levels. The reasons involve red blood cell turnover, spleen function, anemia, and even chemical interference from alcohol metabolism, and the practical consequences for diagnosis and treatment can be serious.
Why A1C Hinges on Red Blood Cell Survival
A1C measures how much sugar has attached itself to hemoglobin, the oxygen-carrying protein inside red blood cells. Because red blood cells typically circulate for about 120 days before the body recycles them, A1C gives a weighted average of blood sugar exposure over roughly two to three months. The key word is “weighted”: more recent weeks count more heavily than older ones, because the youngest red blood cells have had the least time to accumulate sugar on their hemoglobin.
This means anything that changes how long red blood cells survive directly changes the A1C reading, independent of what blood sugar is actually doing. If red blood cells are destroyed faster than normal, they spend less time in circulation and collect less sugar. The A1C drops, not because blood sugar improved, but because the “measuring tape” got shorter. This relationship between A1C and red blood cell turnover is well established and sits at the heart of why liver disease distorts the test.1PubMed Central. Glycated Hemoglobin (HbA1c): Clinical Applications of a Mathematical Concept
How Cirrhosis Pushes A1C Downward
Advanced liver disease attacks A1C reliability through several routes at once. In cirrhosis, the spleen often enlarges because of increased pressure in the portal vein, a condition called portal hypertension. An oversized spleen traps and destroys red blood cells faster than it should, shortening their lifespan. Bleeding from the gastrointestinal tract, common in people with portal hypertension, also removes red blood cells from circulation. Meanwhile, the liver’s own illness can suppress bone marrow function and create nutritional deficiencies in iron, folate, or vitamin B12 that impair the production of new red blood cells.2PubMed Central. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
The result is a population of red blood cells that skews younger than normal. Since younger cells have had less time to accumulate glycated hemoglobin, the A1C reading drops. Blood transfusions, which are common in advanced liver disease, compound the distortion unpredictably: donor red blood cells have their own glycation history, which may not match the recipient’s blood sugar levels at all. Any single one of these factors would nudge A1C downward. In cirrhosis, they often stack on top of each other.
How Far Off Can A1C Actually Be?
The gap between what A1C says and what blood sugar is actually doing can be surprisingly wide. In a study comparing people with diabetes who had cirrhosis against those without it, the cirrhosis group had a median A1C of about 5.9% while the non-cirrhosis group had a median of 7.7%, even though their actual blood sugar concentrations were statistically similar. In effect, the liver disease shaved roughly 1.8 percentage points off the A1C reading.3Diabetic Medicine. Utility of HbA1c assessment in people with diabetes awaiting liver transplantation
Another study looked specifically at people with decompensated cirrhosis, meaning the liver had lost enough function to cause visible complications. Nearly half the patients showed a discrepancy of more than 0.5% between their calculated and measured A1C, and about one in eight had a discrepancy greater than 1.5%. The degree of anemia was the strongest predictor of how far off the A1C landed: the lower the hemoglobin, the more the A1C undershot reality.4International Journal of Endocrinology. Glycated Hemoglobin Levels in Patients with Decompensated Cirrhosis
A smaller study of compensated cirrhosis found that 40% of participants had A1C results below the normal non-diabetic reference range, despite evidence of glucose problems.2PubMed Central. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases So the issue is not limited to the sickest patients, though it does get worse as liver function declines.
The Diagnostic Blind Spot in Hepatogenous Diabetes
Cirrhosis itself can cause diabetes, a condition sometimes called hepatogenous diabetes. The damaged liver loses its ability to clear insulin properly and to store and release glucose in a normal pattern, and the pancreatic beta cells that produce insulin gradually fail under the strain. By some estimates, the majority of people with cirrhosis develop some degree of glucose intolerance, and a meaningful fraction progress to frank diabetes.
Here is the problem: because A1C reads falsely low in this population, hepatogenous diabetes often goes undiagnosed. People with this form of diabetes tend to have normal fasting glucose and normal-looking A1C values, with the abnormality showing up only when their body is challenged with a glucose load.5Wiley Online Library. Hepatogenous diabetes: Is it time to separate it from type 2 diabetes? Missing the diagnosis matters, because uncontrolled blood sugar worsens liver disease outcomes and complicates decisions about liver transplantation.
A study that compared A1C against an oral glucose tolerance test for diagnosing diabetes in cirrhosis found that A1C had an overall sensitivity of about 77% when using the standard 6.5% cutoff. That means nearly a quarter of people who actually had diabetes were missed. Among hospitalized patients, the sensitivity dropped further to roughly 58%, likely because those patients were sicker and had more anemia.6PubMed Central. Utility and Limitations of Glycated Hemoglobin (HbA1c) in Patients with Liver Cirrhosis as Compared with Oral Glucose Tolerance Test for Diagnosis of Diabetes Researchers studying hepatogenous diabetes have noted that because A1C is so often falsely low in cirrhosis, it simply does not help with early diagnosis.7PubMed Central. Hepatogenous Diabetes: An Underestimated Problem of Liver Cirrhosis
Why Blood Sugar Swings Are So Extreme in Liver Disease
Liver disease does not just distort the A1C test. It also creates a blood sugar pattern that is genuinely harder to manage. The liver is the body’s main glucose warehouse: after a meal, it stores sugar as glycogen, and between meals or overnight, it converts that glycogen back into glucose to keep blood sugar stable. When the liver is damaged, both sides of this process suffer.
Postmeal, the liver is slow to absorb glucose from the blood, leading to spikes. During fasting, especially overnight, the shrunken glycogen stores run out quickly, and the liver’s ability to manufacture new glucose from other substrates is impaired. The result is a pattern of high peaks after eating followed by dangerous lows overnight. Researchers have described the metabolic state of someone with chronic liver disease after an overnight fast as resembling what a healthy person looks like after two to three days of starvation.8Scientific Reports. Hypoglycemia measured by flash glucose monitoring system predicts liver-related events in chronic liver disease patients
This rollercoaster pattern makes A1C even less useful as a management tool. An A1C reading is an average: if blood sugar oscillates wildly between 250 and 50, the average might look reasonable even though the person is spending dangerous amounts of time at both extremes. For someone with liver disease, a “good” A1C can conceal both uncontrolled highs and life-threatening lows.
Hepatitis C Treatment and Drug-Induced A1C Distortion
Liver disease and its treatments can introduce a separate layer of A1C distortion that clinicians sometimes overlook. Ribavirin, an antiviral drug used in hepatitis C treatment, causes a reversible form of hemolytic anemia. The drug damages red blood cell membranes, leading to their premature destruction. Because the surviving red blood cells are younger on average, the A1C plummets regardless of what blood sugar is doing.9PubMed Central. Drugs affecting HbA1c levels – Section: Drugs causing hemolysis
Case reports illustrate how extreme this effect can be. One patient’s A1C dropped from 7.5% to 4.0% after starting ribavirin and erythropoietin together, even though fasting blood sugar was still 116 mg/dL. The erythropoietin, given to counteract the anemia, stimulated the bone marrow to produce a wave of brand-new red blood cells, which further diluted the glycated hemoglobin signal. The two drugs together created a synergistic false lowering of A1C.10PubMed. Combination effect of ribavirin and erythropoietin treatment on hemoglobin A1c in a diabetic patient with chronic hepatitis C Another case described a patient whose A1C fell to 4.4% on ribavirin therapy despite persistently high blood glucose, then climbed back to 6.5% after the drug was stopped.9PubMed Central. Drugs affecting HbA1c levels – Section: Drugs causing hemolysis
Although newer direct-acting antivirals have largely replaced ribavirin-based regimens for hepatitis C, ribavirin is still used in some combination therapies. And the broader principle applies to any drug that causes hemolysis or stimulates new red blood cell production. If you are being treated for a liver condition and your A1C suddenly looks much better than your finger-stick readings suggest, the medication could be the reason, not an actual improvement in blood sugar control.11PubMed. Falsely low hemoglobin A1c levels in a patient receiving ribavirin and peginterferon alfa-2b for hepatitis C
How Alcohol Adds Its Own Layer of Interference
Alcohol-related liver disease introduces a chemical complication on top of the red blood cell turnover issues. When the body metabolizes alcohol, it produces acetaldehyde, a reactive molecule that can bind directly to hemoglobin. These acetaldehyde-hemoglobin compounds behave differently on the lab tests used to measure A1C. Early chromatographic methods, which separate hemoglobin variants by their electrical charge, picked up these acetaldehyde adducts in the same region as glycated hemoglobin, potentially pushing the reading falsely upward.
Research has shown that people who drink heavily have elevated levels of these acetaldehyde-modified hemoglobins, but their actual glycated hemoglobin measured by more specific methods may be normal or low.12JCI Insight. Acetaldehyde adducts with hemoglobin Modern assay methods are better at distinguishing acetaldehyde adducts from true glycated hemoglobin, but the interference is not always perfectly eliminated. This means that in alcohol-related liver disease, the A1C could theoretically be pushed in either direction depending on the lab method, the level of ongoing drinking, and the severity of liver damage affecting red blood cell turnover. The net effect in most people with advanced alcoholic cirrhosis still tends to be a falsely low A1C, because the red blood cell destruction from splenomegaly and portal hypertension usually overwhelms any upward nudge from acetaldehyde.
Why the Obvious Alternatives Are Also Flawed
When clinicians realize A1C is unreliable in liver disease, the natural next question is what to use instead. Fructosamine, a test that measures glycated serum proteins and reflects blood sugar over a shorter window of about two to three weeks, seems like an obvious candidate. But liver disease undermines fructosamine too, because the test depends on protein levels in the blood, particularly albumin. Cirrhosis causes the liver to produce less albumin, and it often increases levels of immunoglobulins. A study of patients with cirrhosis found an inverse relationship between albumin levels and fructosamine, and concluded that fructosamine is not useful for assessing blood sugar control in cirrhosis or any condition where protein metabolism is altered.13PubMed. Serum fructosamine concentration in patients with nephrotic syndrome and with cirrhosis of the liver: the influence of hypoalbuminaemia and hypergammaglobulinaemia
Glycated albumin has been explored as another option. It measures sugar attached specifically to albumin rather than to all serum proteins, which avoids the immunoglobulin interference problem. However, it still requires that the body is producing and clearing albumin at a normal rate. In advanced liver disease, albumin turnover is abnormal, so the test can still mislead. It performs better than A1C in some studies, but it is not widely available and is not yet a standard clinical tool in most countries.
The oral glucose tolerance test, which measures how blood sugar responds to a standardized sugar drink over two hours, avoids the red blood cell and protein problems entirely. It provides a snapshot rather than an average, which makes it useful for diagnosing diabetes. It is particularly important in hepatogenous diabetes, where fasting glucose and A1C look normal but post-load glucose is abnormal. The drawback is that it tells you nothing about day-to-day control. You cannot use it to judge whether a treatment regimen is working over time.
Continuous Glucose Monitoring as a Practical Workaround
Continuous glucose monitoring, which uses a small sensor worn on the skin to track glucose levels every few minutes, sidesteps the biological problems that plague A1C and the blood-based alternatives. The sensor measures glucose in the interstitial fluid between cells, so it does not care about red blood cell lifespan, hemoglobin variants, or albumin levels. A CGM system can calculate a glucose management indicator from its data, essentially an estimated A1C based on actual average glucose, and compare it to the lab A1C.
A study using intermittently scanned CGM in patients with liver cirrhosis found meaningful disagreements between the CGM-derived glucose management indicator and the lab A1C. The CGM detected abnormalities in blood sugar control that the A1C alone would have missed entirely.14PubMed Central. Intermittently Scanned Continuous Glucose Monitoring Performance in Patients With Liver Cirrhosis CGM also captures the wild glucose swings described earlier, including the nocturnal hypoglycemia that is particularly common in chronic liver disease, information that no single-point blood test can provide.
The practical barrier is access and cost. Not everyone with liver disease also has a diabetes diagnosis that qualifies them for insurance-covered CGM. And wearing a sensor continuously is a bigger commitment than periodic lab draws. Still, for people with advanced liver disease and known or suspected diabetes, CGM is increasingly recognized as the most trustworthy way to understand what blood sugar is actually doing, and clinical guidelines are starting to incorporate it alongside oral glucose tolerance testing as a recommended diagnostic and management approach.15PubMed. Management of Cirrhosis in Diabetes: A Pragmatic Approach to the Patient
When A1C Can Still Be Trusted
Not every form of liver disease renders A1C useless. The distortion scales with severity. In early-stage fatty liver disease or mild chronic hepatitis without significant fibrosis, the mechanisms that falsely lower A1C, including splenomegaly, chronic bleeding, severe anemia, and major protein disruption, are generally absent. Red blood cells live their normal lifespan, albumin is produced at a normal rate, and the A1C test works about as well as it does in anyone else. One review noted that A1C remains a useful glycemic marker in most patients with mild liver diseases, with accuracy concerns focused on advanced disease.2PubMed Central. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
The gray zone is moderate liver disease, where some fibrosis exists but full-blown cirrhosis has not developed. Here, the A1C may be mildly depressed but not dramatically so, and the degree of distortion is hard to predict for any individual. If your liver doctor describes your disease as compensated cirrhosis (the liver is scarred but still managing its basic jobs), your A1C is likely reading somewhat low, but how much depends on your specific hemoglobin level, spleen size, and whether you have had any bleeding. In this situation, pairing A1C with periodic glucose checks or short-term CGM use gives a much clearer picture than relying on A1C alone.
The sensitivity data from the cirrhosis study mentioned earlier put this in concrete terms. Among outpatients with cirrhosis, the standard A1C cutoff of 6.5% caught about 87% of diabetes cases, which is not terrible but still means roughly one in seven diagnoses was missed. Among sicker, hospitalized patients, the detection rate dropped to 58%, meaning nearly half were missed.6PubMed Central. Utility and Limitations of Glycated Hemoglobin (HbA1c) in Patients with Liver Cirrhosis as Compared with Oral Glucose Tolerance Test for Diagnosis of Diabetes If you have cirrhosis and your A1C comes back in the normal range, that does not necessarily mean your blood sugar is fine. Treat it as a data point that needs corroboration, not as a clean bill of health.
What Happens to A1C After a Liver Transplant
One of the more revealing pieces of evidence comes from watching what happens to A1C after a liver transplant. When the diseased liver is replaced with a healthy one, the portal hypertension resolves, the spleen shrinks toward normal size, anemia improves, and red blood cells start living their full lifespan again. Predictably, A1C values rise, sometimes sharply, even without any change in blood sugar control. Clinicians managing post-transplant patients know to expect this: a person whose A1C was 5.5% before transplant may see it climb to 7% or higher afterward, not because their diabetes got worse, but because the test is finally reflecting their actual glucose exposure.
This post-transplant rebound also exposes people who had undiagnosed hepatogenous diabetes. Some patients who never carried a diabetes diagnosis before surgery find themselves clearly diabetic by standard A1C criteria once the liver stops distorting the measurement. Others who did have known diabetes may need their treatment regimens significantly adjusted, because the “good control” their A1C had been reporting was an illusion. The immunosuppressive drugs used after transplantation can also worsen insulin resistance, adding a genuine metabolic insult on top of the unmasking of a previously hidden one. Managing blood sugar through this transition period requires close monitoring, and CGM has become increasingly valuable in this setting for the same reasons it helps before transplant.